NEW YORK, April 27, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on PIRS, PTLA, PLX, and RDUS which can be accessed for free by signing up to www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com scans Pieris Pharmaceuticals Inc. (NASDAQ: PIRS),
On Thursday, shares in Boston, Massachusetts headquartered Pieris Pharmaceuticals Inc. recorded a trading volume of 241,830 shares. The stock ended the session 1.87% lower at $6.31. The Company's shares have gained 168.51% in the past twelve months. The stock is trading below its 50-day moving average by 14.57%. Moreover, shares of Pieris Pharma, which discovers and develops anticalin-based drugs in the US, have a Relative Strength Index (RSI) of 35.78. Get the full research report on PIRS for free by clicking below at:
South San Francisco, California headquartered Portola Pharmaceuticals Inc.'s stock closed the day 2.73% higher at $34.56 with a total trading volume of 526,460 shares. The Company's shares have advanced 11.63% in the past month. The stock is trading below its 50-day moving average by 4.94%. Additionally, shares of Portola Pharma, which develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation, have an RSI of 50.13. Gain free access to the research report on PTLA at:
Shares in Karmiel, Israel-based Protalix BioTherapeutics Inc. recorded a trading volume of 159,182 shares. The stock ended yesterday's trading session 2.21% lower at $0.42. The stock is trading below its 50-day moving average by 25.42%. Furthermore, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have an RSI of 31.06. Signing up today on Wall St. Equities will give you access to the latest report on PLX at:
Waltham, Massachusetts headquartered Radius Health Inc.'s stock finished Thursday's session 2.39% higher at $32.97 with a total trading volume of 355,264 shares. The stock is trading below its 50-day moving average by 7.42%. Additionally, shares of Radius Health, which develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology, have an RSI of 38.94.
On March 29th, 2018, research firm Leerink Partners initiated an 'Outperform' rating on the Company's stock, with a target price of $53 per share. Register now for today's free coverage on RDUS at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.orgPhone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/biotech-stocks-research-reports-released-on-pieris-pharma-portola-pharma-protalix-biotherapeutics-and-radius-health-300637919.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...
Acanthosis nigricans is a skin condition in which discoloration and hyperpigmentation of the skin ...
Gastrointestinal Bleeding refers to hemorrhage that occurs from one or more portions of the ...View All